Affimed Archives

Podcast 1 Sep 2023

Beyond Biotech podcast 61 – Blood Cancer Awareness Month

On this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed’s CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to tackle blood cancers. One of the main challenges in treating blood cancers is the limited options for therapeutic intervention. Treatment relies primarily on chemotherapy, which […]

September 1, 2023

News and Trends 16 Nov 2020

Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal

Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up an emerging trend of harnessing our innate immune system to treat cancer. According to the deal’s terms, Affimed will receive €51M upfront to license to Roivant a preclinical-stage antibody drug for several undisclosed types of cancer. Roivant will handle the […]

November 16, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 10 Oct 2018

Cancer Immunotherapy Phase I on Hold After Patient Death

The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them. Affimed was testing its immunotherapy AFM11 in 33 patients diagnosed with white blood cell cancer in two Phase I trials. One trial tested the therapy […]

October 10, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Jun 2017

What Cancer Therapies did European Biotechs Showcase at ASCO 2017?

Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO 2017 meeting in Chicago. European biotech was in the spotlight during this year’s edition of the American Society of Clinical Oncology (ASCO) meeting, with impressive results from some of the most novel approaches under development to fight multiple forms of cancer. From a […]

June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

affimed afmd 2015 results immuno oncology

News and Trends 31 Mar 2016

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Affimed from Heidelberg had a ‘formative year’ (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology. Affimed is a Biopharma focused on discovering and developing highly targeted cancer immunotherapies. It is also one of our trendiest NASDAQ-listed European Biotechs (and the only one […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

biotech nasdaq stock top biopharma finance 2016

News and Trends 23 Feb 2016

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock exchange in the world, based in New York, and the largest for high-tech companies. It seems to be the real test for a European biotech to […]

February 23, 2016 - 6 minutesmins - By Philip Hemme

merck msd keytruda immunoncology lymphoma hodgkins affimed

News and Trends 26 Jan 2016

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of Merck’s (MSD) anti-PD-1 therapy (Keytruda), with Affimed’s proprietary drug for the treatment of patients with Hodgkin lymphoma. The phase Ib trial will focus on patients whose disease has relapsed or is refractory to chemotherapy, including treatment with the marketed antibody-drug-conjugate […]

January 26, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a […]

November 24, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Oct 2015

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin’s Lymphoma. An undisclosed shareholder has just increased its position in the company by purchasing an additional 3.3 million shares, leading to a total of €19.2M private investment. Affimed Therapeutics is a NASDAQ-listed biotech […]

October 19, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Sep 2014

Affimed secures almost $30M in Financing to continue its clinical development

Affimed Therapeutics today announced that it has closed a $15.7 million (€11.7 million) Series E equity funding led by Affimed’s current investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed. In addition, the Company has signed a $14 million (€10.5 million) loan agreement with Perceptive Advisors, leading to a total of […]

September 3, 2014 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us